There is a poster on Resverlogix website

Here is an excerpt re: the deal

Near Term Development Points • The US FDA and Resverlogix have now confirmed the final BETonMACE2 clinical plans. – Filing of a New Drug Application (NDA) with the FDA is possible following unequivocal efficacy at an interim analysis of BETonMACE2 - 2023 – All or most BETonMACE2 patients to receive top standard of care, including SGLT2 inhibitors – BETonMACE2 to increase enrichment of chronic kidney disease (CKD) patients – Based on existing results, the FDA encouraged the evaluation of a non-alcoholic fatty liver disease (NAFLD) subgroup as well as related exploratory endpoints • Development, Option 1, Resverlogix will now finalize it’s ongoing negotiations with Major Pharmaceutical companies to determine a suitable partner for co-developing apabetalone. Codevelopment discussions include the following: ▪ Resverlogix will receive a significant upfront payment H2, 2020. ▪ The Phase 3b clinical trial will be funded by the partnering company - $120 to $150 MM USD. ▪ Our new partner can supply their SGLT2 diabetes drug as the co-medication. Thus providing the pharma partner with valuable marketing material and the ability to launch a fixed dose combination product with patent coverage until 2040. ▪ The deal will also include substantial milestone and royalty payments with an M&A right of first refusal option. • Option 2, Resverlogix can finance the Phase 3b trial internally through the sale of 50% of the future royalty stream currently owned by Zenith Capital. Funds would be used to finance BETonMACE2. • Option 3, Resverlogix can finance and launch the Phase 3b trial with internal insider investors. 

Chicagoest